Reviewing MiNK Therapeutics (NASDAQ:INKT) and Atyr PHARMA (NASDAQ:ATYR)

MiNK Therapeutics (NASDAQ:INKT) and Atyr PHARMA (NASDAQ:ATYR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, risk, profitability and institutional ownership.

Profitability

This table compares MiNK Therapeutics and Atyr PHARMA’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MiNK Therapeutics	N/A	N/A	-189.14%
Atyr PHARMA	N/A	-79.44%	-59.16%

Valuation & Earnings

This table compares MiNK Therapeutics and Atyr PHARMA”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiNK Therapeutics	N/A	N/A	-$22.46 million	($2.92)	-2.65
Atyr PHARMA	$235,000.00	1,130.59	-$50.39 million	($0.87)	-3.44

MiNK Therapeutics has higher earnings, but lower revenue than Atyr PHARMA. Atyr PHARMA is trading at a lower price-to-earnings ratio than MiNK Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

MiNK Therapeutics has a beta of 0.15, suggesting that its stock price is 85% less volatile than the S&P 500. Comparatively, Atyr PHARMA has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for MiNK Therapeutics and Atyr PHARMA, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiNK Therapeutics	0	0	2	0	3.00
Atyr PHARMA	0	0	6	1	3.14

MiNK Therapeutics presently has a consensus price target of $37.50, indicating a potential upside of 383.87%. Atyr PHARMA has a consensus price target of $18.60, indicating a potential upside of 522.07%. Given Atyr PHARMA’s stronger consensus rating and higher possible upside, analysts plainly believe Atyr PHARMA is more favorable than MiNK Therapeutics.

Institutional and Insider Ownership

2.9% of MiNK Therapeutics shares are owned by institutional investors. Comparatively, 61.7% of Atyr PHARMA shares are owned by institutional investors. 20.6% of MiNK Therapeutics shares are owned by company insiders. Comparatively, 3.7% of Atyr PHARMA shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Atyr PHARMA beats MiNK Therapeutics on 9 of the 13 factors compared between the two stocks.

About MiNK Therapeutics

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

About Atyr PHARMA

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.